Gray Institute for Radiation Oncology and Biology, Oxford University, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom.
Cancer Res. 2010 Apr 1;70(7):2984-93. doi: 10.1158/0008-5472.CAN-09-4040. Epub 2010 Mar 16.
The effectiveness of radiotherapy treatment could be significantly improved if tumor cells could be rendered more sensitive to ionizing radiation (IR) without altering the sensitivity of normal tissues. However, many of the key therapeutically exploitable mechanisms that determine intrinsic tumor radiosensitivity are largely unknown. We have conducted a small interfering RNA (siRNA) screen of 200 genes involved in DNA damage repair aimed at identifying genes whose knockdown increased tumor radiosensitivity. Parallel siRNA screens were conducted in irradiated and unirradiated tumor cells (SQ20B) and irradiated normal tissue cells (MRC5). Using gammaH2AX foci at 24 hours after IR, we identified several genes, such as BRCA2, Lig IV, and XRCC5, whose knockdown is known to cause increased cell radiosensitivity, thereby validating the primary screening end point. In addition, we identified POLQ (DNA polymerase ) as a potential tumor-specific target. Subsequent investigations showed that POLQ knockdown resulted in radiosensitization of a panel of tumor cell lines from different primary sites while having little or no effect on normal tissue cell lines. These findings raise the possibility that POLQ inhibition might be used clinically to cause tumor-specific radiosensitization.
如果能够在不改变正常组织敏感性的情况下,使肿瘤细胞对电离辐射(IR)更敏感,那么放射治疗的效果将得到显著提高。然而,许多决定内在肿瘤放射敏感性的关键治疗性可开发机制在很大程度上仍是未知的。我们已经对涉及 DNA 损伤修复的 200 个基因进行了小干扰 RNA(siRNA)筛选,旨在鉴定那些敲低后能提高肿瘤放射敏感性的基因。在照射和未照射的肿瘤细胞(SQ20B)和照射的正常组织细胞(MRC5)中进行了平行的 siRNA 筛选。利用照射后 24 小时的 γH2AX 焦点,我们鉴定了一些基因,如 BRCA2、Lig IV 和 XRCC5,其敲低已知会导致细胞放射敏感性增加,从而验证了主要筛选终点。此外,我们还鉴定出 POLQ(DNA 聚合酶)是一个潜在的肿瘤特异性靶标。随后的研究表明,POLQ 敲低导致来自不同原发部位的一系列肿瘤细胞系的放射增敏作用,而对正常组织细胞系几乎没有或没有影响。这些发现提出了这样一种可能性,即 POLQ 抑制可能在临床上被用于引起肿瘤特异性放射增敏作用。